Hudson Bay Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Hudson Bay Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,000	Closed	-$454K	–	764
2023 Q3	$454K	Sell	10,000 -20,000	-67%	-$1.03M	﹤0.01%	605
2023 Q2	$1.68M	Sell	30,000 -30,000	-50%	-$1.7M	0.01%	527
2023 Q1	$2.71M	Sell	60,000 -21,600	-26%	-$1.05M	0.02%	457
2022 Q4	$3.32M	Buy	81,600 +66,600	+444%	+$3.53M	0.03%	477
2022 Q3	$980K	Hold	15,000	–	–	0.01%	853
2022 Q2	$912K	Sell	15,000 -20,000	-57%	-$1.18M	0.01%	950
2022 Q1	$2.2M	Buy	35,000 +11,300	+48%	+$710K	0.03%	672
2021 Q4	$1.8M	Buy	23,700 +6,200	+35%	+$542K	0.02%	712
2021 Q3	$1.96M	Buy	17,500 +10,000	+133%	+$1.26M	0.03%	631
2021 Q2	$1.21M	Sell	7,500 -7,500	-50%	-$912K	0.01%	704
2021 Q1	$1.83M	Buy	+15,000	New	+$2.26M	0.02%	583

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Hudson Bay Capital Management's CRSP Position: Q4 2023 in Review

Hudson Bay Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 10,000 shares — an estimated $454K sold.

Hudson Bay Capital Management first reported a position in CRSP in Q1 2021 and held it in 11 quarters. The position peaked at $3.32M in Q4 2022. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Hudson Bay Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 10,000 CRISPR Therapeutics shares in Q4 2023, an estimated $454K.
Hudson Bay Capital Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 11 quarters.
Hudson Bay Capital Management's CRISPR Therapeutics position peaked at $3.32M in Q4 2022.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Hudson Bay Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.